Changes in gastrointestinal motility influence the absorption of desmopressin

European Journal of Clinical Pharmacology

Volumn 55, Issue 4, 1999, Pages 305-309

  Callreus T ^a   Lundahl, J ^b   Hoglund P ^a   Bengtsson, P ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Ferring Pharmaceuticals   (Sweden)

Author keywords

Absorption; Desmopressin; Gastrointestinal motility

Indexed keywords

DESMOPRESSIN; ERYTHROMYCIN; LOPERAMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GASTROINTESTINAL MOTILITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTI-BACTERIAL AGENTS; DEAMINO ARGININE VASOPRESSIN; DRUG INTERACTIONS; ERYTHROMYCIN; FEMALE; GASTROINTESTINAL AGENTS; GASTROINTESTINAL MOTILITY; HUMANS; INTESTINAL ABSORPTION; LOPERAMIDE; MALE; MIDDLE AGED; RENAL AGENTS;

EID: 0032936954     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050633     Document Type: Article

References (16)

1. 1. Vilhardt H (1990) Basic pharmacology of desmopressin. A review. Drug Invest 2: 2-8
2. 2. Cobb W, Pare S, Reichlin S (1978) Neurogenic diabetes insipidus: management with dDAVP (1-desamino-8-D arginine vasopressin). Ann Intern Med 88: 183-188
3. 3. Robinson A (1976) DDAVP in the treatment of central diabetes insipidus. New Engl J Med 294: 507-511
4. 4. Sukhai RN (1993) Enuresis nocturna: long term use and safety aspects of Minirin (desmopressin) spray. Regul Pept 45: 309-310
5. 5. Matthiesen TB, Rittig S, Djurhuus JC, Norgaard JP (1994) A dose titration, and an open 6-week efficacy and safety study of desmopressin tablets in the management of nocturnal enuresis. J Urol 151: 460-463
6. 6. David J (1993) Desmopressin and hemostasis. Regul Pept 45: 311-317
7. 7. Fjellestad-Paulsen A, Laborde K, Kindermans C, Czernichow P (1993) Water-balance hormones during long-term follow-up of oral dDAVP treatment in diabetes insipidus. Acta Pediatr 82: 752-757
8. 8. Fjellestad-Paulsen A, Höglund P, Lundin S, Paulsen O (1993) Pharmacokinetics of 1-desamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers. Clin Endocrinol 38: 177-182
9. 9. Ritting S, Jensen AR, Jensen KT, Pedersen EB (1998) Effect of food intake on the pharmacokinetics and antidiuretic activity of oral desmopressin (DDAVP) in hydrated normal subjects. Clin Endocrinol 48: 235-241
10. 10. Weber FH, Richards RD (1993) Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. Am J Gastroenterol 88: 485-490
11. 11. Awouters F, Megens A, Verlinden M, Schuurkes J, Niemegeers C, Janssen PAJ (1993) Loperamide. Survey of studies on mechanism of its antidiarrheal activity. Dig Dis Sci 38: 977-995
12. 12. Lundin S, Melin P, Vilhardt H (1985) Plasma concentrations of 1-desamino-8-D-arginine vasopressin after intragastric administration in the rat. Acta Endocrinol 108: 179-183
13. 13. Fjellestad-Paulsen A, Söderberg-Ahlm C, Lundin S (1995) Metabolism of vasopressin, oxytocin, and their analogues in the human gastrointestinal tract. Peptides 16: 1141-1147
14. 14. Fjellestad-Paulsen A, d'Agay-Abensour L, Höglund P, Rambaud J-C (1996) Bioavailability of 1-desamino-8-D-arginine vasopressin with an enzyme inhibitor (aprotinin) from the small intestine in healthy volunteers. Eur J Clin Pharmacol 50:491-495
15. 15. Robson WLM, Norgaard JP, Leung AKC (1996) Hyponatremia in patients with nocturnal enuresis treated with DDAVP. Eur J Pediatr 155: 959-962
16. 16. Jackson EK (1996) Vasopressin and other agents affecting the renal conservation of water. In: Hardman JG, Limbird LE (eds) Goodman and Gilman's: the pharmacological basis of therapeutics, 9th edn. McGraw-Hill, New York, pp 715-731